NUWE Nuwellis, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1506492 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.3%
TTM net income YoY16.9%
TTM EPS YoY197.4%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—
Margins
Gross margin70.8%
Operating margin-135.8%
Net margin-152.8%
FCF margin-136.6%
EBITDA margin-134.2%
Returns
ROE-200.1%
ROA-128.4%
ROIC (approx.)-815.9%
Asset turnover0.84x
Leverage & solvency
Liabilities / assets26.7%
Debt / equity0.00x
Current ratio3.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-13.6%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8.27M | $8.74M |
| Cost of revenue | $3.15M | $3.06M |
| Gross profit | $5.12M | $5.68M |
| R&D expense | $2.71M | $3.21M |
| SG&A expense | $13.52M | $13.46M |
| Operating income | -$11.11M | -$10.99M |
| Pretax income | -$17.52M | -$11.16M |
| Income tax | $5,000 | $5,000 |
| Net income | -$17.52M | -$11.16M |
| EBITDA | -$10.91M | -$10.68M |
| EPS (basic) | -25.39 | -353.30 |
| EPS (diluted) | -25.39 | -353.30 |
| Weighted avg. shares (diluted) | 690,145 | 31,601 |
| Balance sheet | ||
| Cash & equivalents | $1.08M | $5.09M |
| Receivables | $1.49M | $1.73M |
| Inventory | $1.91M | $1.72M |
| Current assets | $5.19M | $8.86M |
| PP&E, net | $368,000 | $478,000 |
| Intangibles | $0 | — |
| Total assets | $6.12M | $9.86M |
| Current liabilities | $3.03M | $2.56M |
| Total liabilities | $3.49M | $3.33M |
| Shareholders' equity | $2.62M | $6.53M |
| Shares outstanding | 5,342 | 104,142 |
| Cash flow statement | ||
| Operating cash flow | -$10.81M | -$9.59M |
| Capital expenditure | $90,000 | $60,000 |
| Free cash flow | -$10.90M | -$9.65M |
| Investing cash flow | -$90,000 | -$60,000 |
| Financing cash flow | $6.94M | $10.96M |
| Depreciation & amortization | $200,000 | $310,000 |
| Stock-based compensation | $127,000 | $478,000 |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.